

Please type a plus sign (+) inside this box


**COPY OF PAPERS
ORIGINALLY FILED**

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|---|---|---|--|
| Substitute for form 1449A/PTO | |  | | Complete if Known | |
| | | | | Application Number 09/960,708 Filing Date September 19, 2001 First Named Inventor CRABTREE, GERALD R. Group Art Unit 1635 Examiner Name Unassigned Attorney Docket Number STAN-201 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | | |
| Sheet | 1 | of | 1 | | |

RECEIVED

TECH CENTER 1800/290

| U.S. PATENT DOCUMENTS | | | | | | |
|--------------------------------|-----------------------|-----------------------|-----------------------------------|--|--|---|
| Examiner Initials ¹ | Cite No. ¹ | U.S. Patent Documents | | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| M | | 6,096,515 | | Crabtree et al. | 08-01-2000 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------------|-----------------------|--------------------------|---------------------|-----------------------------------|--|--|
| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Documents | | | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| M | | HERNANDEZ et al. "Selective Inhibition of Vascular Endothelial Growth Factor-mediated Angiogenesis by Cyclosporin A; Roles of the Nuclear Factor of Activated T Cells and Cyclooxygenase 2" J. Exp Med., Vol. 193, No. 5, March 5, 2001 pp 607-620 | |
| | | | |
| | | | |
| | | | |
| | | | |


| | | | |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 11/17/03 |
|--------------------|---|-----------------|----------|

¹EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

| | | |
|--|--|---------------------------------|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | ATTY. DOCKET NO. STAN201 | SERIAL NO. 09/960,708 |
| | APPLICANT: Gerald R. Crabtree | |
| | FILING DATE: Septmber 19, 2001 | GROUP: 1635 |



U.S. PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------------|----------|-----------------|-------|----------|-------------------------------|
| <i>M</i> | AA 6,096,515 | 08/01/00 | Crabtree et al. | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Document Number | Date | Country | Class | Subclass | Translation |
|-------------------------|----------|---------|-------|----------|-------------|
| <i>M</i> AB Wo 00/30671 | 06/02/00 | PCT | | | Yes No |
| | | | | | |

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----------|----|---|
| <i>A</i> | AC | Folkman et al "Angiogenesis" <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 16, Issue of June 5, pp. 10931-10934, 1992 |
| <i>M</i> | AD | Clipstone et al. "Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation" <i>Nature</i> , Vol. 357, 25 June 1992, pps 695-697 |
| <i>M</i> | AE | Flanagan et al, "Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A" <i>Nature</i> , Vol 352 29 August 1991 pps 803-807 |
| <i>M</i> | AF | Emmel et al. "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation" <i>Science</i> , Vol 246, 22 December 1989 pps 1617-1620 |
| <i>M</i> | AG | Shaw et al, "Identification of a Putative Regulator of Early T Cell Activation Genes" <i>Science</i> , Vol 241, 8 July 1988 pps, 202-205 |
| <i>M</i> | AH | Durand et al. "A 275 Basepair fragment at the 5' end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the t cell antigen receptor" <i>J. Exp. Med</i> The Rockefeller University Press, Vol. 165, February 1987 pps 395-407 |
| <i>A</i> | AI | Durand et al, "Characterization of Antigen Receptor Response Elements within the Interleukin-2 Enhancer", <i>Molecular and Cellular Biology</i> , April 1988, 0.1715-1724 |

F:\DOCUMENT\STAN (Stanford)\201\Form PTO-1449.doc

| | |
|---|---------------------------------|
| EXAMINER | DATE CONSIDERED 11/15 |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |